Evelo Biosciences Accounts Payable

Evelo Biosciences (EVLO) currently reports a accounts payable of $530K as of September 2023. That compares with $1.6M in the prior-year period — down 66.1% year over year. Use the charts on this page to explore Evelo Biosciences's accounts payable history and peer comparisons.

Evelo Biosciences's accounts payable decreased from $1.6M to $530K — a 66.1% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Evelo Biosciences reported $530K in accounts payable as of September 2023. That compares with $1.6M in the prior-year period — down 66.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $530K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Evelo Biosciences, and consider following EVLO for alerts when major investors trade the stock.

Evelo Biosciences is classified in the Healthcare sector. On accounts payable, it currently shows $530K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EVLO with unrelated industries.